drugset / Trial / NCT01336738

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

NCT01336738

Phase 2 Completed 266 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.

Timeline

Start
2011-06
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-04991532 Small molecule 150 mg
Subject PF-04991532 Small molecule 450 mg
Subject PF-04991532 Small molecule 750 mg
Comparator Sitagliptin Small molecule 100 mg